2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2683 Variation in ferritin reference interval across US hospitals and implications for the diagnosis of iron deficiency

Carla Isabel Borre, MD, MPH, Lara Soueid2, Darci Block3, Candido E Rivera, MD4, Surbhi Shah, MBBS, MD5, Marwan Shaikh6, Alexandra Wolanskyj-Spinner, MD7, Ewa Wysokinska, MD8, Stephan Thome, MD9, Zoey Harris, MD10, Emily Wolf, MD11, Michelle Elliott, MD12, Meera Sridharan, MD PhD13, Richard C. Godby, MD14, Leslie Padrnos, MD15, Rajiv Pruthi, MBBS16, Ronald Go, MD17
1 Mayo Clinic, Rochester, Minnesota, United States
2 American University of Beirut, Ain El-Mreissé, Lebanon
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Jacksonville, Florida, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Jacksonville, Florida, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Phoenix, Arizona, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States

Background: Ferritin is the most commonly used biomarker for diagnosing iron deficiency (ID). Unlike laboratory tests that are interpreted using clinical decision limits, ferritin is typically reported against a reference interval, making the lower reference limit a key determinant of whether patients are identified as iron deficient. For decades, the World Health Organization (WHO) and US Centers for Disease Control and Prevention (CDC) have recommended a threshold below 15 ng/mL to define ID, and most US laboratories have set their reference intervals near this cutoff. Recent physiologic and clinical data suggest that ferritin values well above 15 ng/mL are associated with depleted iron stores and meaningful symptoms, and the 2025 American Society of Hematology (ASH) draft guideline for ID diagnosis proposes a unified threshold of 30 ng/mL or below. Whether US laboratory reference intervals align with this emerging standard has not been systematically described. 

Methods: After Mayo Clinic Institutional Review Board exemption, we conducted a cross-sectional study of adult ferritin reference intervals obtained via the Epic electronic medical record and Care Everywhere health information exchange (reflecting the referral catchment of Mayo Clinic sites), with values current as of 2024-2026. For each laboratory, we recorded the lower and upper bounds of the ferritin reference interval separately for adult male and female ranges. Each laboratory was classified by setting (academic vs community) and US Census Bureau region. Continuous variables are reported as median (interquartile range [IQR]) and range. Ferritin assay manufacturer information was not captured.

Results: We obtained ferritin reference intervals from 150 US institutions across 35 states; 109 laboratories (73%) were classified as community and 41 (27%) as academic. Institutions represented the Midwest (57%), South (21%), West (19%), and Northeast (3%). A male reference interval was identified for 87 laboratories and a female reference interval for 88; both were available for 25. The lower limit of the ferritin reference interval varied 6.5-fold for male and 10-fold for female reference intervals. The median lower limit of the male ferritin reference interval was 24 ng/mL (IQR, 18-30; range, 10-65), and the median lower limit for females was 13 ng/mL (IQR, 10-15; range, 5-50). When compared with the ASH 2025 draft threshold of 30 ng/mL or below, 60 of 87 laboratories (69%) reporting a male reference interval and 85 of 88 (97%) reporting a female reference interval used a lower limit below 30 ng/mL. Fifteen laboratories (17%) used a male lower limit below the WHO/CDC threshold of 15 ng/mL, and 61 (69%) used a female lower limit below 15 ng/mL. Reference limits were modestly lower at community than academic laboratories for male (median 22 [IQR 18-29] vs 26 [IQR 22-30]; <30: 74% vs 56%) and nearly identical for female intervals (median 11 [IQR 9-15] vs 13 [IQR 11-16]; <30: 97% vs 97%).

Conclusion: In this cross-sectional study of 150 US institutions, adult ferritin reference interval lower limits varied substantially across laboratories and were consistently set well below the 30 ng/mL threshold proposed in the 2025 ASH draft guideline for iron deficiency. The discordance was greatest for women: nearly all laboratories reporting a female reference interval used a lower limit below 30 ng/mL, and the median female lower limit was only 13 ng/mL. These findings highlight an underappreciated distinction between a reference interval, which describes the central distribution of a presumed-healthy population and is how ferritin is currently reported, and a decision limit, which defines the concentration at which diagnosis or treatment is triggered, as used for reporting hemoglobin A1c and cholesterol. Because clinicians rely on the reported reference interval to identify iron deficiency, patients, particularly women, may not be offered evaluation or treatment. Transitioning ferritin toward decision-limit reporting would require addressing inter-assay variability, defining thresholds from outcome-based data, and considering whether sex-specific limits are warranted, similarly to the WHO hemoglobin definition of anemia. Our findings support the need for a consistent, evidence-based ferritin reporting standard across US laboratories to reduce diagnostic variability and support equitable detection of iron deficiency.

Carla Isabel Borre, MD, MPH: No relevant conflicts of interest to declare.